Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline
02 Juin 2020 - 7:00AM
Sanofi to present oncology strategy, provide
update on portfolio and emerging pipeline
PARIS – April 2, 2020 – Sanofi Chief Executive
Officer Paul Hudson along with R&D and commercial leaders will
provide an overview of Sanofi’s oncology strategy and progress
update of its related key products and pipeline programs. Sanofi’s
oncology strategy is focused on four core therapeutic areas with
four anchor treatments the company believes have the potential to
transform patient care.
The four areas of strategic focus within
oncology, including multiple myeloma, skin, lung, and breast
cancers. Sanofi’s four anchor oncology treatments include Sarclisa®
(isatuximab-irfc), an anti-CD38 monoclonal antibody and Libtayo®
(cemiplimab-nwlc), a PD-1 checkpoint inhibitor1 and the pipeline
programs – an investigational anti-CEACAM 5 antibody drug conjugate
and SERD (‘859), an investigational oral selective estrogen
receptor degrader.
“We are rapidly building momentum with the
execution of our oncology strategy, with several developments on
both our pipeline and marketed treatments. Additionally, we are
assembling a world-class development and marketing team to support
our growth in this core area,” said Hudson. “We believe our efforts
and treatments have the potential to make a significant difference
in the lives of people living with cancer.”
“We’ve developed a focused oncology strategy,
and are making significant clinical progress to support our
ambitions,” said John Reed, M.D., Ph.D., Global Head of Research
and Development at Sanofi. “With a deep toolbox of therapeutic
platforms enabling us to discover highly differentiated molecules,
Sanofi has a tremendous opportunity to continue our momentum and
build a sustainable presence in oncology.”
The virtual investor event will be held today
from 4:00-5:30 pm CET/10:00-11:30 am EST. Sanofi speakers
include:
- Paul Hudson, Chief Executive Officer
- John Reed, Global Head of Research and Development
- Dietmar Berger, Chief Medical Officer and Global Head of
Development
- Peter Adamson, Global Head of Development, Oncology
- Alex Zehnder, Global Franchise Head, Oncology
Additional information about today’s oncology
presentation can be found at:
https://www.sanofi.com/en/investors/financial-results-and-events/investor-presentations/2020-oncology-presentation
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations Contact Ashleigh Koss Tel.: +1 908
205 2572Ashleigh.Koss@sanofi.com Quentin Vivant Tél.: +33 (0)1 53
77 46 46mr@sanofi.com |
Investor
Relations Contact Felix Lauscher Tel.: +33 (0)1 53 77 45
45 ir@sanofi.com |
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
COVID-19 will have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a
whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2019. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
1 Partnered with Regeneron
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024